Upadacitinib – Medxy AI

Rapid, Durable Benefit of Upadacitinib Across Oligo‑ and Polyarticular Psoriatic Arthritis: Primary Findings from the Real‑World UPJOINT Study

By MedXY 12/04/2025

In the multicenter UPJOINT observational study, upadacitinib produced rapid and sustained improvements in minimal disease activity in both oligo- and polyarticular psoriatic arthritis over 48 weeks, with a safety profile consistent with prior trials.

Gastroenterology news Specialties

Durable Remission and Safety of Upadacitinib in Moderate to Severe Ulcerative Colitis: Insights from the Phase 3 U-ACTIVATE Long-Term Extension Interim Analysis

By MedXY 08/14/2025

Interim data from the U-ACTIVATE study demonstrate sustained clinical and endoscopic remission and a consistent safety profile for upadacitinib up to 3 years in moderate to severe ulcerative colitis.

Clinical Updates news Rheumatology Specialties

Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence

By MedXY 08/02/2025

Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unresponsive to conventional therapies.